Description
Repligen’s Record $209 Million Quarter — Is Wall Street Missing the BioLife Opportunity?
Repligen Corporation reported third-quarter 2026 revenue of $209 million, marking a record quarter and surpassing its prior peak from the second quarter of 2022. Organic growth was 12.5%, with growth driven primarily by proteins and chromatography franchises, offsetting an 11% decline in filtration revenues, impacted by divestitures and delayed system shipments pushed into 2027. Adjusted operating margins expanded by 170 basis points year over year to 15.9%, supported by disciplined cost control and modest operating expense growth of 5%. Adjusted net income increased 16% to $30 million, with adjusted earnings per share rising 15% to $0.53. The company’s cash position remained strong at $863 million at quarter-end before deploying approximately $550 million in early October for the acquisition of BioLife.



